Access cutting-edge fsgs treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access fsgs specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related fsgs treatment provided free
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an
Sponsor: Dimerix Bioscience Pty Ltd
Check if you qualify for this fsgs clinical trial in Phoenix, AZ
If you're searching for fsgs treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced fsgs specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.